support shown for fixed-duration combination ibrutinib venetoclax for cll patients
Published 3 years ago • 94 plays • Length 4:46Download video MP4
Download video MP3
Similar videos
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
11:23
captivate: fixed-duration first-line treatment with ibrutinib plus venetoclax for cll/sll
-
7:36
fixed-duration ibrutinib and venetoclax for first-line cll
-
8:46
new data supports long term efficacy of venetoclax-obinutuzumab for cll patients
-
1:23
captivate: fixed-duration ibrutinib plus venetoclax in patients with cll/sll
-
4:12
positive long-term data of ibrutinib venetoclax as first-line cll treatment
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
1:53
achieving undetectable mrd with ibrutinib plus venetoclax for cll
-
8:11
ibrutinib combined with venetoclax for cll treatment - 4-year follow-up
-
1:31
dr. smith on the rationale behind the fixed duration trial for ibrutinib/venetoclax in cll
-
1:07
ibrutinib plus venetoclax as a treatment option for cll
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
3:56
venetoclax/rituximab combo for chronic lymphocytic leukemia shows reduced disease progression
-
24:22
highlight of cll-related 2016 fda approvals: venetoclax
-
12:05
venetoclax combinations, safety and efficacy
-
2:41
fixed-duration vs continuous therapy in cll
-
4:45
frontline ibrutinib venetoclax in cll: results from a fixed duration cohort of the captivate study
-
4:10
ibrutinib and venetoclax continue to provide benefits for patients with chronic cll and sll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data